The case report of AQP4 and MOG IgG double positive NMOSD treated with subcutaneous Ofatumumab. Gou B, Yang P, Feng J, Li Y, et al. J Neuroimmunol 2023;376:578035.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Gou B, Yang P, Feng J, Li Y, et al. The case report of AQP4 and MOG IgG double positive NMOSD treated with subcutaneous Ofatumumab. J Neuroimmunol 2023;376:578035.
PMID: 36716560